JW (Cayman) Therapeutics Co. Ltd. (HK:2126) has released an update.
JW (Cayman) Therapeutics Co. Ltd., a leader in cell immunotherapy, has announced a significant milestone with the Chinese National Medical Products Administration’s approval of their Carteyva® product for treating relapsed or refractory mantle cell lymphoma in adults. This marks the third marketing approval for Carteyva®, making it the first CAR-T cell therapy product in China for this condition. The approval was based on promising clinical study results, where the majority of patients achieved complete remission, highlighting Carteyva® as a breakthrough in addressing the unmet medical needs in mantle cell lymphoma treatments.
For further insights into HK:2126 stock, check out TipRanks’ Stock Analysis page.
